News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The business and product range of Ipca and that of Unichem complements each others business and product range
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
Bridging the gap between histopathology and molecular pathology
Subscribe To Our Newsletter & Stay Updated
